May 16, 2023 · The ODYSSEY OUTCOMES trial showed that use of alirocumab, taken every other week, significantly reduces ischemic events, including all-cause mortality and MI.
Missing: Polyvascular | Show results with:Polyvascular
Nov 11, 2019 · ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated ...
Data from the large ODYSSEY OUTCOMES trial in over 18,000 patients after an ACS showed significant reductions in major cardiovascular events in several risk ...
Aug 21, 2020 · ODYSSEY OUTCOMES compared alirocumab with placebo in patients with recent ACS and dyslipidaemia despite intensive statin treatment. Estimated ...
Sep 3, 2019 · Dive into the research topics of 'Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial'.
CONCLUSION: In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyVD is associated with high risks of MACE and death. The large ...
Apr 1, 2022 · Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES Trial ... clinical trial. Eur Heart J ...
... ODYSSEY OUT-. COMES Committees and Investigators. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYS-. SEY OUTCOMES trial ...
Aug 19, 2024 · Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol 2019;74:1167 ...
Aug 26, 2019 · Identifying those who stand to gain the most is important because the drugs are still costly, even with recent price cuts.